MedTrace Logo

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

NCT02491398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 494

Last updated 2020-10-06

No results posted yet for this study

Summary

This study is intended for Chronic Lymphocytic Leukemia patients who have already undergone a first or second treatment with drugs named bendamustine and rituximab. It will observe the results of this treatment and evaluate its efficacy and side effects.

Conditions

Interventions

DRUG

Bendamustine + Rituximab

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Antonio Cuneo · Ematologia; Azienda Ospedaliera di Ferrara

  • Gian Matteo Rigolin · Ematologia; Azienda Ospedaliera di Ferrara

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491398 on ClinicalTrials.gov